The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.

Sci Rep · 2016 · PMC4904223 · PMID 27292568

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

TR-764 demonstrated highly significant antivascular activity also in a murine and human model of melanoma, respect to the lead compound CA-4P, both in acute and after prolonged treatment.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.